NewsRoom Articles - Page 50 of 154 - PsychedelicNewsWire (PNW)

TuesdaySep 06, 2022 11:55 am

Psychedelics, Near-Death Experiences Both Reduce Fear of Dying

A new study has found that psychedelics reduce depression and anxiety in patients with life-threatening illnesses, which in turn lessens their fear of dying and death. The study, which involved researchers from Johns Hopkins Medicine surveying 3,192 individuals, reported its findings in the “PLOS ONE” journal. For their study, the researchers administered an online survey to these participants from December 2015 to April 2018. The researchers divided the study subjects into groups based on those who had had psychedelic experiences brought on by psychedelics and those who had undergone a nondrug-linked near-death experience. The majority of the subjects had undergone…

FridaySep 02, 2022 11:07 am

Important Factors to Consider When Designing Psychedelic Clinical Trial Protocols

Companies have been investing big in psychedelic research in recent years, pouring some $60 million into psychedelic companies in 2018 and 2019. With the massive surge in interest in psychedelics among the mainstream and scientific communities, this investment is expected to balloon to more than $2 billion globally. But for the Food and Drug Administration to approve psychedelic-assisted therapies, researchers will have to prove via a series of clinical trials that the substances are effective and safe for human use. Given the unique mind-altering effects associated with hallucinogenic drugs such as psilocybin, ketamine, and MDMA, developers will have to approach…

ThursdaySep 01, 2022 11:26 am

Study Shows Psilocybin Helps Alcoholics Reduce Drinking

New research has found that psilocybin may help individuals with alcohol use disorders decrease their drinking. Figures show that roughly 20 million individuals in America struggle with substance use disorders. Currently, only a trio of drugs have been approved by the FDA for the treatment of this disorder. However, side effects such as nausea and vomiting are impeding adherence to those approved treatments. Earlier studies have shown that psilocybin possesses the potential to treat various addiction disorders, including opioid use disorder, alcohol use disorder and smoking. Psilocybin works by reshaping the neural networks in the brain associated with habits related…

WednesdayAug 31, 2022 1:33 pm

Researchers Push DEA to Rescind Psychedelic Restriction Plan

In April, the DEA announced its intent to place certain hallucinogens in Schedule I, which would make it harder for researchers to conduct studies investigating the therapeutic potential of those substances. This is in addition to criminalizing said substances. However, after scientists from Emory University and Panacea Plant Sciences challenged this action, the agency decided to withdraw the proposal altogether. In a recently released notice, the agency stated that it would rescind the ban on DOC (2,5-dimethoxy-4-chloroamphetamine) and DOI (2,5-dimethoxy-4-iodoamphetamine) and would instead publish a new proposed rule. The DEA’s justification for the original ban wasn’t backed by sufficient evidence…

WednesdayAug 31, 2022 11:30 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Pioneering Efforts as Studies, Research Show Psilocybin’s Potential in Treating AUD

A new study shows promise in treating alcohol addiction with psychedelic mushroom compound, psilocybin These results align with efforts and expectations of Cybin, a leading ethical biopharmaceutical company championing psilocybin After receiving FDA approval, the company is moving forward with a first-in-human clinical trial evaluating CYB003 A new study published in JAMA Psychiatry offers hope for those struggling with alcoholism (https://ibn.fm/jV5o9), showing promise in treating alcohol addiction with the psychedelic compound psilocybin. This news aligns with initiatives of Cybin (NEO: CYBN) (NYSE American: CYBN), a leading ethical biopharmaceutical company, which has a drug in development, CYB003, for the treatment of alcohol…

TuesdayAug 30, 2022 12:36 pm

Psychedelics Company Raises More than $10M in Seed Funding to Advance Ketamine Therapy

Freedom Biosciences is a leading biotechnology platform focused on developing next-generation psychedelic therapies. The company was founded in April 2021 by Dina Burkitbayeva and Dr. John Krystal. Burkitbayeva is also the cofounder of PsyMed Ventures while Krystal is the psychiatry department chair at Yale University. The company has raised $10.5 million in seed financing and focused on advancing a ketamine therapy for the treatment of major depressive disorder. Ketamine is a dissociative drug that is commonly used as an anesthetic, as well as a drug to manage acute pain. Recent studies have found that the drug may also be useful…

MondayAug 29, 2022 12:38 pm

How Psychedelics Startups Are Improving Their Resilience

After decades of prohibition and criminalization, psychedelic policies are finally starting to loosen up amid a significant surge in psychedelics research. The resulting scientific studies into the probable benefits and risks of hallucinogenic drugs have revealed that the substances can indeed be effective against a variety of mental health conditions, especially when combined with psychotherapy. As such, the nascent psychedelic industry has attracted numerous startups that would like to develop novel psychedelic-assisted therapies. The industry is projected to be worth $6.63 billion in 2026, and plenty of companies are keen on taking a slice of these profits for themselves. But…

FridayAug 26, 2022 12:20 pm

DEA Delay Leaves Synthetic Psychedelics in Legal Limbo

Psychedelics are currently experiencing a renaissance that has been characterized by a significant surge in scientific research, public interest and reform efforts. Said to be effective against mental health conditions such as eating disorders, anxiety, depression and post-traumatic stress disorder, psychedelics have been subject to several legislative efforts across the country as activists have tried to get them legalized for medical use. There are a wide variety of psychedelics, including a class of artificial psychedelics that are synthesized in a laboratory rather than extracted from a natural source. In 2021, the U.S. Drug Enforcement Agency (DEA) announced that it was…

FridayAug 26, 2022 9:45 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Leading Out in Transformation of Psychedelic Sector

Psilocybin is seeing a “research resurgence” focused on how the substance changes the brain's connectivity patterns CYBN is leading the industry in developing proprietary psychedelic-based therapeutics The company’s lead investigational molecule has the potential to treat major depressive disorder and alcohol use disorder The status of psilocybin is evolving as a result of mounting public acceptance and growing evidence that the substance delivers remarkable health benefits. Cybin (NEO: CYBN) (NYSE American: CYBN) is on the leading edge of this transformation, as the clinical-stage biopharmaceutical company focuses on progressing psychedelics to therapeutics by offering a new standard of care for mental-health disorders…

ThursdayAug 25, 2022 12:12 pm

Study Finds More Than 5.5 Million Adults in the US Use Hallucinogens

Hallucinogens are drugs that alter an individual’s feelings and thoughts as well as the awareness of their surroundings. These drugs are usually classified as either dissociative drugs or classic hallucinogens. Classic hallucinogens include LSD, MDMA, ayahuasca, THC and mescaline while dissociative drugs include PCP (phencyclidine), ketamine and DXM, which is also known as lean. New research has found that the use of hallucinogens in America has significantly risen among adults in the last 20 years. This research is the first to provide formal statistical analyses of trends on the use of hallucinogens in the last two decades. The study was…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000